KRAS and non-small cell lung carcinoma: confirmed that EMT is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small-cell lung cancer 46, suggesting that the EMT process plays a critical role in KRAS mutation-driven tumorigenesis and therapeutic resistance.